World Encephalitis Day: Enceph-IG Trial
22 February 2021World Encephalitis Day on February 22 is a global awareness day where individuals and families affected by encephalitis (inflammation of the brain) come together to shine a light on the condition. The Centre for Trials Research at Cardiff University is fully co-ordinating the Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults-A Randomised Double-Blind Placebo-Controlled Trial (Enceph-IG Trial)
Autoimmune encephalitis is swelling in the brain caused by the immune system attacking in error. It can cause people to become confused, drowsy, act out of character, and have seizures. It is a rare condition effecting approximately 6,000 people a year in the UK, according to the Encephalitis Society, and even though there are a range of treatment options available to tackle both the causes and symptoms of encephalitis, there isn’t a specific targeted treatment. The Enceph-IG Trial is hoping to help change that.
Typically, patients receive steroids but some patients are given intravenous immunoglobulin (IVIG) because some clinicians think it may help speed up recovery. There have been very few clinical trials looking at recovery time and IVIG use in those with autoimmune encephalitis, so we don’t really know if it is effective at speeding up recovery. IVIG can be associated with significant side effects and is very expensive because it is developed from donated blood. The aim of the current trial is to evaluate how effective early treatment with IVIG is in speeding up recovery from autoimmune encephalitis.
We are looking to recruit 356 patients, from 50 hospitals across the UK. The trial will be double blind, this means neither the patients, their families, nor the clinicians treating them will know whether they received IVIG or not. This is to avoid accidentally biasing the results. Once patients are recruited and randomised they will receive steroids and IVIG, or steroids and a placebo (a product that looks identical but which does not contain the active ingredient) for 5 days. Patients will be asked to regularly report on their recovery, and they will be assessed by a clinician at 2 weeks, 3 months, and 12 months after they enter the trial.
We are still very early on in the trial set up phase but the impact of COVID on research has meant that we have had to rethink a lot of our standard procedures. A trial comprises of lots of documents, such as detailed protocols and patient information sheets, which are developed collaboratively with the multi-disciplinary team. It has been a challenge to work on all of these documents remotely. Many of the grant collaborators are clinicians and during COVID they have been very busy with their clinical work or were drafted to cover COVID related healthcare. It has been so important before each meeting to identify the key priorities so that we can maximise the time we have with the collaborators and keep the trial moving forward. Given the delays experienced, we have been able to progress and were able to submit our trial for ethical review recently. We will also be utilising more digital tools for data collection and for training site staff in trial activities in order to streamline processes for our clinical teams at sites. We are hoping to start opening our first group of NHS sites in the summer.
Trials in rare disease areas can be difficult to do, so it is very important that any trial actually meets the needs of the specific patient group. The Enceph-IG trial has strong links with the Encephalitis Society, the leading charity advocating for Encephalitis patients and their families in the UK, and their patient advocate group has provided input from the inception of the trial. During the grant development stage, patients and their families were consulted on what they thought the most meaningful outcome would be patients, data collection methods, and frequency of follow up visits. Currently, we have a patient and public representative from Encephalitis Society sitting on our trial management group, and others sitting on our trial steering group.
We are very early on in the life cycle of this trial, so we won’t see results for another 5 years but because this is a rare disease area we are hoping that this will be a landmark trial and improve patient treatment for those with encephalitis.
Acknowledgements:
The trial is funded through the NIHR NIHR Efficacy and Mechanism Evaluation programme (NIHR17/60/67).
The Chief Investigator is Professor Tom Solomon, Chair of Neurology University of Liverpool, @RunningMadProf
Trial Collaborators: Dr Benedict Michael (University of Liverpool), Dr Simon Keller (University of Liverpool), Dr Michael Griffiths (University of Liverpool), Dr Perry Moore (Salford Royal NHS Foundation Trust), Prof Richard Pleass (Liverpool School of Hygiene and Tropical Medicine), Dr Ava Easton (Encephalitis Society), Associate Prof Sarosh Irani (University of Oxford), Dr David Gillespie (Centre for Trials Research), Dr Emma Thomas-Jones (Centre for Trials Research), Dr Sylviane Defres (The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool), Dr Mark Ellul (University of Liverpool), Dr Michael Lunn (University College London Hospital NHS Foundation Trust), Dr Michael Zandi (University College London Hospital NHS Foundation Trust)
The trial is sponsored by the University of Liverpool and fully coordinated by the Centre for Trials Research, Cardiff University.
- October 2024
- September 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- December 2023
- November 2023
- September 2023
- July 2023
- June 2023
- April 2023
- March 2023
- February 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- November 2021
- September 2021
- July 2021
- June 2021
- May 2021
- March 2021
- February 2021
- December 2020
- November 2020
- September 2020
- August 2020
- July 2020
- January 2020
- December 2019
- October 2019
- September 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- December 2017
- October 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- October 2016
- August 2016
- June 2016
- April 2016
- March 2016
- February 2016